JP2004529117A5 - - Google Patents

Download PDF

Info

Publication number
JP2004529117A5
JP2004529117A5 JP2002571052A JP2002571052A JP2004529117A5 JP 2004529117 A5 JP2004529117 A5 JP 2004529117A5 JP 2002571052 A JP2002571052 A JP 2002571052A JP 2002571052 A JP2002571052 A JP 2002571052A JP 2004529117 A5 JP2004529117 A5 JP 2004529117A5
Authority
JP
Japan
Prior art keywords
antagonist
histamine
medicament
preparation
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002571052A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004529117A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/003975 external-priority patent/WO2002072093A2/en
Publication of JP2004529117A publication Critical patent/JP2004529117A/ja
Publication of JP2004529117A5 publication Critical patent/JP2004529117A5/ja
Pending legal-status Critical Current

Links

JP2002571052A 2001-02-08 2002-02-06 認知欠陥障害の処置における二重のｈ３／ｍ２アンタゴニストの使用 Pending JP2004529117A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26735201P 2001-02-08 2001-02-08
PCT/US2002/003975 WO2002072093A2 (en) 2001-02-08 2002-02-06 Use of dual h3/m2 antagonists with a bipiperidinic structure in the treatment of cognition deficit disorders

Publications (2)

Publication Number Publication Date
JP2004529117A JP2004529117A (ja) 2004-09-24
JP2004529117A5 true JP2004529117A5 (enExample) 2005-12-22

Family

ID=23018432

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002571052A Pending JP2004529117A (ja) 2001-02-08 2002-02-06 認知欠陥障害の処置における二重のｈ３／ｍ２アンタゴニストの使用

Country Status (6)

Country Link
US (1) US6906081B2 (enExample)
EP (1) EP1408965A2 (enExample)
JP (1) JP2004529117A (enExample)
AU (1) AU2002253929A1 (enExample)
CA (1) CA2436083A1 (enExample)
WO (1) WO2002072093A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1373251A2 (en) 2001-03-13 2004-01-02 Schering Corporation Non-imidazole compounds as histamine h3 antagonists
MXPA05000193A (es) * 2002-06-24 2005-04-08 Schering Corp Derivados de indol utiles como antagonistas de la histamina h2.
WO2004066960A2 (en) * 2003-01-28 2004-08-12 Schering Corporation Combination of h1, h3 and h4 receptor antagonists for treatment of allergic and non-allergic pulmonary inflammation, congestion and allergic rhinitis
ATE370135T1 (de) * 2003-07-18 2007-09-15 Glaxo Group Ltd Substituierte piperidine als histamin-h3- rezeptorliganden
GB0420831D0 (en) 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
WO2006036686A2 (en) * 2004-09-24 2006-04-06 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
US9132135B2 (en) * 2004-09-24 2015-09-15 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
US8541452B2 (en) * 2005-10-06 2013-09-24 Guy Chouinard Method for treating binge-eating disorder
US7728031B2 (en) 2006-02-24 2010-06-01 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole derivatives
US8026240B2 (en) 2007-09-11 2011-09-27 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole N-oxides
DK2271218T3 (en) * 2008-03-27 2017-09-11 Chase Pharmaceuticals Corp USE AND COMPOSITION TO TREAT DEMENS
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
WO2014039627A1 (en) 2012-09-05 2014-03-13 Chase Pharmaceuticals Corporation Anticholinergic neuroprotective composition and methods
EP4251148A1 (en) * 2020-11-27 2023-10-04 Richter Gedeon Nyrt. Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2624734A (en) * 1950-04-29 1953-01-06 Hoffmann La Roche Bipiperidine derivatives
GB8916947D0 (en) 1989-07-25 1989-09-13 Smith Kline French Lab Medicaments
GB9115740D0 (en) 1991-07-20 1991-09-04 Smithkline Beecham Plc Medicaments
US5807872A (en) 1992-12-16 1998-09-15 Schering Corporation Imidazoylalkyl substituted with a six membered nitrogen containing heterocyclic ring
DK0618913T3 (da) 1991-12-18 1996-10-14 Schering Corp Imidazolyl eller imidazoylalkyl substitueret med en 4- eller 5-leddet nitrogenholdig heterocyclisk ring
US5633250A (en) 1991-12-18 1997-05-27 Schering Corporation Imidazoylalkyl substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms
US5352707A (en) 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
US5446057A (en) 1993-09-24 1995-08-29 Warner-Lambert Company Substituted tetrahydropyridine and piperidine carboxylic acids as muscarinic antagonists
NZ330898A (en) 1993-11-15 2000-01-28 Schering Corp Phenyl-alkyl imidazoles as H3-receptor antagonists in particular for the treatment of inflammation
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
US5935958A (en) 1996-07-01 1999-08-10 Schering Corporation Muscarinic antagonists
US5952349A (en) 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
US5977138A (en) 1996-08-15 1999-11-02 Schering Corporation Ether muscarinic antagonists
US6034251A (en) 1997-11-07 2000-03-07 Schering Corporation Phenyl-alkyl-imidazoles
US5990147A (en) * 1997-11-07 1999-11-23 Schering Corporation H3 receptor ligands of the phenyl-alkyl-imidazoles type
US6066636A (en) 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists
US6100279A (en) 1998-11-05 2000-08-08 Schering Corporation Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom
US6294554B1 (en) 1999-09-22 2001-09-25 Schering Corporation Muscarinic antagonists

Similar Documents

Publication Publication Date Title
JP2007145875A5 (enExample)
JP2004529117A5 (enExample)
JP2003503454A5 (enExample)
JP2009502743A5 (enExample)
EP2298757A3 (en) Urea compounds active as vanilloid receptor antagonist for the treatment of pain
JP2004504376A5 (enExample)
JP2004534850A5 (enExample)
JP2019503365A5 (enExample)
HUP0500107A3 (en) 1-alkyl-1-azoniabicyclo[2.2.2.]octane carbamate derivatives, pharmaceutical compositions comprising thereof and their use as muscarinic receptor antagonists
JP2007514005A5 (enExample)
IL171591A (en) Quinuclidine derivatives, process for their preparation and use thereof for the manufacture of medicaments for the treatment of conditions mediated by the muscarinic m3 receptor
SI1551803T1 (sl) Azabiciklo derivati kot antagonisti muskarinskih receptorjev
IL164440A0 (en) New pharmaceutical composition containing fibanserin polymorph a
JP2007516193A5 (enExample)
MXPA04003298A (es) Compuestos de piperidina como antagonistas muscarinicos.
JP2008513510A5 (enExample)
HUP0401805A2 (hu) Pulmonális betegségek kezelésére szolgáló vegyületek
JP2008516004A5 (enExample)
AU2003214535A8 (en) Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2004067510A8 (en) 3,6-disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2005062894A3 (en) Co-administration of dopamine-receptor binding compounds
ATE386738T1 (de) Flavaxat-derivate als muscarin-rezeptor antagonisten
HUP0401325A3 (en) Isoxazolopyridinones useful in the treatment of parkinson's disease, process for their preparation and pharmaceutical compositions containing the compounds
EP2301625A3 (en) Compositions and methods for treating cognitive disorders
JP2005513036A5 (enExample)